ArticleCancer reports (Hoboken, N.J.)2026
Assessing Practice Patterns of Antidepressant Medication and Tamoxifen Use Among Patients With Hormone Receptor-Positive Breast Cancer.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome commonly prescribed antidepressants inhibit CYP2D6, an enzyme that metabolizes tamoxifen into its active metabolite, endoxifen. This inhibition could theoretically decrease the efficacy of tamoxifen, which could hypothetically lead to higher breast cancer recurrence rates and mortality. There is inconsistent data reported on the potential drug-drug interaction between concomitant use of tamoxifen and CYP2D6-inhibiting antidepressants.
aimWe investigated prescribing patterns of concomitant tamoxifen and antidepressant medications. METHODS AND
resultsOur study population included adult women ≥ age 18, with stage 0-IV breast cancer who were treated at the Cleveland Clinic, received tamoxifen, and were concurrently prescribed at least 1 antidepressant medication. Patients diagnosed between 2016 and 2021 were identified from a tumor registry database. Among the 405 included patients, 74.8% were taking at least 1 antidepressant before initiating tamoxifen, while 25.2% were started on antidepressant therapy after beginning tamoxifen. Following tamoxifen initiation, 66.3% of patients who had been on an antidepressant continued with the same medication. Among those who switched antidepressants, 16.8% changed to a serotonin-norepinephrine reuptake inhibitor (SNRI), 12.8% changed to a different selective serotonin reuptake inhibitor (SSRI), and 2.6% changed to another class of antidepressant.
conclusionsThere is awareness of tamoxifen and antidepressant interaction among healthcare providers. However, differences in prescription patterns across providers exist. Individualizing care and, when appropriate, opting for antidepressants with weak or no CYP2D6 inhibition that are equally effective in treating mood disorders or other conditions may be important. While no adherence or outcomes data are presented here, a collaborative, interdisciplinary approach may help support consistent and effective oncologic and behavioral health patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.